Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Related BIIB
Are There Any Winners Left In The Biotech Space?
How Gilead And Johnson & Johnson's Tumble Could've Burned These Hedge Funds
Don't Panic Over Recent Tech Turmoil (Fox Business)
Related AMGN
Are There Any Winners Left In The Biotech Space?
Is Illumina Worth Adding To Your Portfolio?
The Tech Industry is Vanishing Before Our Eyes (Fox Business)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas

 

Related Articles (AMGN + BIIB)

Around the Web, We're Loving...

Get Benzinga's Newsletters